ZURA BIO LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.19 USD | +0.58% |
|
+10.90% | +11.13% |
| May. 10 | Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating | MT |
| May. 09 | Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 377M |
|---|---|---|---|---|---|
| Net income 2024 * | -36M | Net income 2025 * | -59M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-11.7
x | P/E ratio 2025 * |
-7.38
x | Employees | 15 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 27.52% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.58% | ||
| 1 week | +10.90% | ||
| Current month | +21.55% | ||
| 1 month | +65.81% | ||
| 3 months | +33.08% | ||
| 6 months | +22.70% | ||
| Current year | +11.13% |
1 week
4.52
6.35
1 month
3.136.35
Current year
2.006.35
1 year
2.0013.00
3 years
2.0037.55
5 years
2.0037.55
10 years
2.0037.55
| Managers | Title | Age | Since |
|---|---|---|---|
Someit Sidhu
FOU | Founder | 34 | 22-01-17 |
Robert Lisicki
CEO | Chief Executive Officer | 57 | Jan. 07 |
Verender Badial
DFI | Director of Finance/CFO | 51 | 23-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Amit Munshi
CHM | Chairman | 56 | 23-02-28 |
Steven Schoch
BRD | Director/Board Member | 64 | 23-02-28 |
Sandeep Kulkarni
BRD | Director/Board Member | 43 | 22-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.87% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 6.05 | +0.83% | 439,335 |
| 24-05-16 | 6 | +15.61% | 397,224 |
| 24-05-15 | 5.19 | +0.58% | 128,198 |
| 24-05-14 | 5.16 | +7.72% | 256,541 |
| 24-05-13 | 4.79 | +2.35% | 162,379 |
End-of-day quote Nasdaq, May 14, 2024
More quotes
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.05
USD
Average target price
17.8
USD
Spread / Average Target
+194.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.13% | 377M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.84B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- ZURA Stock